Home > Pulmonology > ERS 2018 > COPD: Triple therapy, MABA and antibiotics > ICS: To Use or Not to Use?

ICS: To Use or Not to Use?

Presented By
Dr Gary Ferguson, Pulmonary Research Institute of Southeast Michigan, USA
Conference
ERS 2018
Trial
KRONOS

The role of ICS in COPD is an area of intense interest, said Dr Gary Ferguson (Pulmonary Research Institute of Southeast Michigan, USA) at the beginning of his lecture [16]. The recently updated GOLD guidelines recommend initiation of ICS treatment for patients with high exacerbation risk only [17], due to concerns over the risk:benefit ratio of chronic ICS use compared to other therapies. However, real-world studies have shown that ICS are prescribed across the spectrum of disease severity [18].

The benefits of ICS/LAMA/LABA triple therapy are not well studied in certain patient populations, such as patients who are considered to have a lower risk of exacerbations. Budesonide/glycopyrronium/formoterol metered-dose inhaler (MDI), formulated using an innovative co-suspension delivery technology, is a fixed-dose triple combination in development for patients with COPD. “KRONOS was partly a regulatory study to evaluate triple vs dual combination therapy”, stated Dr Ferguson. ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on